Maarten de Château
Director/Board Member at XINTELA AB
Profile
Maarten de Château is the founder and Chief Executive Officer of Cormorant Pharmaceuticals AB, which was founded in 2010.
He is currently the Chief Executive Officer & Director at Sixera Pharma AB, Buzzard Pharmaceuticals AB, Cordivest AB, MetaCurUm Biotech AB, and Director at Beactica Therapeutics AB, Xintela AB, Atrogi AB, Chateau Holding AB, Targinta AB, Cavis Technologies AB, Strike Pharma AB, Amarna Holding BV, Saare Consulting AB, and Member-Supervisory Board at Amarna Therapeutics BV.
He has also held positions as Director at OxThera AB, AddBIO AB, Gesynta Pharma AB, Nylof Holding AB, and Evident Life Försäkring AB.
Dr. de Château holds a doctorate degree from the University of Lund.
Maarten de Château active positions
| Companies | Position | Start |
|---|---|---|
| XINTELA AB | Director/Board Member | 2020-12-31 |
Cormorant Pharmaceuticals AB
 Cormorant Pharmaceuticals AB BiotechnologyHealth Technology Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden. | Chief Executive Officer | 2010-10-13 |
| Cavis Technologies AB | Director/Board Member | - |
| Amarna Holding BV | Director/Board Member | - |
| MetaCurUm Biotech AB | Chief Executive Officer | - |
Buzzard Pharmaceuticals AB
 Buzzard Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château. | Chief Executive Officer | - |
| Chateau Holding AB | Director/Board Member | - |
| Cordivest AB | Chief Executive Officer | - |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Director/Board Member | - |
| ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Maarten de Château
| Companies | Position | End |
|---|---|---|
| ░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░ ░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Maarten de Château
| University of Lund | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Private companies | 19 |
|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
Beactica Therapeutics AB
 Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Distribution Services |
AddBIO AB
 AddBIO AB BiotechnologyHealth Technology AddBIO AB provides bone implant technology solutions. It offers Zolidd, a bioactive nanolayer with a bone strengthening drug. The firm's Zolidd is used in the areas of dental and trauma implants. It also offers Zolidiser, a machine to add bone-strengthening drugs to implants. The company was founded by Per Aspenberg and Trine Vikinge in 2008 and is headquartered in Linköping, Sweden. | Health Technology |
Cormorant Pharmaceuticals AB
Cormorant Pharmaceuticals AB BiotechnologyHealth Technology Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden. | Health Technology |
Atrogi AB
 Atrogi AB BiotechnologyHealth Technology Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden. | Health Technology |
Sixera Pharma AB
 Sixera Pharma AB Pharmaceuticals: GenericHealth Technology Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden. | Health Technology |
| Chateau Holding AB | |
Gesynta Pharma AB
 Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Health Technology |
Nylof Holding AB
 Nylof Holding AB Investment Banks/BrokersFinance Nylof Holding AB provides security brokerage services. The private company is based in Stockholm, Sweden. | Finance |
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
| Cavis Technologies AB | |
Buzzard Pharmaceuticals AB
Buzzard Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château. | Health Technology |
| Evident Life Försäkring AB | |
| Cordivest AB | |
| MetaCurUm Biotech AB | |
Strike Pharma AB
 Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | Commercial Services |
| Amarna Holding BV | |
| Saare Consulting AB |
- Stock Market
- Insiders
- Maarten de Château